


### **Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

### **Listing of Claims**

Claims 1 - 37 (canceled).

Claim 38 (new): A method of treating in a mammal a disorder in which the modulation of CCR5 receptors is implicated comprising administering to said mammal an effective amount of a compound of Formula I



wherein R<sup>1</sup> is C<sub>3-6</sub> cycloalkyl optionally substituted by one or more fluorine atoms, or C<sub>1-6</sub> alkyl optionally substituted by one or more fluorine atoms, or C<sub>3-6</sub> cycloalkylmethyl optionally ring-substituted by one or more fluorine atoms, and

R<sup>2</sup> is phenyl optionally substituted by one or more fluorine atoms,  
or a pharmaceutically acceptable salt or solvate thereof.

Claim 39 (new): A method of treating in a mammal a respiratory disorder selected from adult respiratory distress syndrome (ARDS), bronchitis, chronic bronchitis, chronic obstructive pulmonary disease, cystic fibrosis, asthma, emphysema, rhinitis and chronic sinusitis, which comprises administering to said mammal an effective amount of a compound of Formula I according to claim 38.

Claim 40 (new): A method of treating in a mammal an inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, graft rejection, including a kidney or a lung allograft, endometriosis, type I diabetes, a renal disease, chronic pancreatitis, an inflammatory lung condition or chronic heart failure which comprises administering to said mammal an effective amount of a compound of Formula I according to claim 38.

Claim 41 (new): A method of treating HIV infection comprising administering an effective amount of a compound of Formula I according to claim 38.

Claim 42 (new): A method of treating HIV infection comprising administering an effective amount of a compound selected from the group consisting of:

N-{(1S)-3-[3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-exo-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl}cyclobutanecarboxamide;

N-{(1S)-3-[3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-exo-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl}cyclopentanecarboxamide;

N-{(1S)-3-[3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-exo-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl}-4,4,4-trifluorobutanamide;

N-{(1S)-3-[3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-exo-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl}-4,4-difluorocyclohexanecarboxamide; and

N-{(1S)-3-[3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-exo-8-azabicyclo[3.2.1]oct-8-yl]-1-(3-fluorophenyl)propyl}-4,4-difluorocyclohexanecarboxamide;

or a pharmaceutically acceptable salt or solvate thereof.

Claim 43 (new): The method of claim 40 wherein said graft rejection is kidney or lung allograft rejection.

Claim 44 (new): A method according to claim 38 wherein said modulation comprises reducing or inhibiting the CCR5 receptor-associated responses in said mammal.